Swain, S. M., Miles, D., Kim, S., Im, Y., Im, S., Semiglazov, V., . . . Cortés, J. (2020). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The lancet. Oncology, 21(4), . https://doi.org/10.1016/S1470-2045(19)30863-0
Chicago-Zitierstil (17. Ausg.)Swain, Sandra M., et al. "Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer (CLEOPATRA): End-of-study Results from a Double-blind, Randomised, Placebo-controlled, Phase 3 Study." The Lancet. Oncology 21, no. 4 (2020). https://doi.org/10.1016/S1470-2045(19)30863-0.
MLA-Zitierstil (9. Ausg.)Swain, Sandra M., et al. "Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer (CLEOPATRA): End-of-study Results from a Double-blind, Randomised, Placebo-controlled, Phase 3 Study." The Lancet. Oncology, vol. 21, no. 4, 2020, https://doi.org/10.1016/S1470-2045(19)30863-0.